NCT04362774View on ClinicalTrials.gov

ORBERA365 Post-Marketing Clinical Follow-up Study

TerminatedOBSERVATIONAL
Enrollment

25

Participants

Timeline

Start Date

February 23, 2021

Primary Completion Date

February 21, 2023

Study Completion Date

October 10, 2023

Conditions
ObesityOverweight
Interventions
DEVICE

ORBERA365

Behavioral modification program in conjunction with endoscopic placement of a single ORBERA365 Intragastric Balloon, filled with saline to an inflation volume between 400cc and 700cc with 2mL of Methylene blue (10mg/mL)

Trial Locations (1)

41018

Obymed, Seville

Sponsors
All Listed Sponsors
lead

Apollo Endosurgery, Inc.

INDUSTRY

NCT04362774 - ORBERA365 Post-Marketing Clinical Follow-up Study | Biotech Hunter | Biotech Hunter